X4 Pharmaceuticals Announces Positive FDA Type C Outcome for 4WARD Phase 3

What Happened X4 Pharmaceuticals, Inc. (XFOR) announced on September 8, 2026 that it received a positive outcome from a Type C meeting with the U.S. Food and Drug Administration regarding its global 4WARD Phase 3 clinical trial. The company filed a press release about the meeting outcome as Exhibit 99.1 to its Form 8-K; the report was signed by CFO David Kirske on September 8, 2026.

Key Details

• Date filed: September 8, 2026 (Form 8-K, Item 8.01 Other Events).
• Subject: Positive outcome of FDA Type C meeting concerning the global 4WARD Phase 3 clinical trial.
• Press release: Filed as Exhibit 99.1 and incorporated by reference in the 8-K.
• Form signature: Signed by David Kirske, Chief Financial Officer and Treasurer.

Why It Matters A positive Type C meeting outcome with the FDA is a regulatory milestone that can clarify trial design, endpoints, or next steps for a Phase 3 program. For investors, this announcement may reduce some regulatory uncertainty around X4’s 4WARD Phase 3 development plan and could influence the program’s timeline or perceived risk. The 8-K itself does not disclose financial impacts, changes to guidance, or other corporate actions—it's a notice that the company received favorable feedback and has publicly disclosed that outcome.